| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1501 | |
| Phytochemical name or plant extracts | Isolate f6l | |
| PMID | 23803103 | |
| Literature evidence | Considering the cytotoxicity profile and its mode of action, f6l might represent a new promising compound with potential for development as an anticancer drug with low or no toxicity to non-cancer cells used in this study. | |
| IUPAC name | 4-[[(2E)-3,3-dimethyl-2-[2-[4-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]ethylidene]indol-1-yl]methyl]benzoic acid | |
| Phytochemicals’ class or type of plant extracts | Polyunsaturated fatty acid | |
| Source of phytochemicals or plant Extracts | Cassia alata | |
| Geographical availability | Belize, Bolivia, Brazil North, Brazil Northeast, Brazil Southeast, Brazil West-Central, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, French Guiana, Guyana, Haiti, Honduras, Jamaica, Leeward Is., Mexico Southwest, Nicaragua, Panamá, Paraguay, Peru, Puerto Rico, Southwest Caribbean, Suriname, Trinidad-Tobago, Venezuela, Windward Is. | |
| Plant parts | Leaves | |
| Other cancers | Breast cancer, Bladder cancer, Colorectal cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | 16 µg/ml against MCF-7 17 µg/ml against T24 | |
| Potency | Isolate f6l was further evaluated using MTT assay and morphological and biochemical investigations, which likewise showed selectivity to MCF-7, T24, and Col 2 cells with IC50 values of 16, 17, and 17 µg/ml, respectively. | |
| Cell line/ mice model | MCF-7,a breast carcinoma, SKBR-3, another breast carcinoma, T24 a bladder carcinoma, Col 2, a colorectal carcinoma, and A549, a non- small cell lung adenocarcinoma. | |
| Additional information | Spectral characterization of isolate f6l revealed that it contained polyunsaturated fatty acid esters. | |
| PubChem ID | 155803668 | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:316402-2 | |
| Safety | Considering the cytotoxicity profile and its mode of action, f6l might represent a new promising compound with potential for development as an anticancer drug with low or no toxicity to non-cancer cells used in this study. |